Press & News

People are different and so is their cancer, patients should be treated individually.

Article from BioStock

October 18, 2018

IR

BioStock article about CE-IVD certification. Article is in Swedish.

https://www.biostock.se/2018/10/2curexs-ce-ivd-markning-ett-avgorande-steg-mot-lansering-av-inditreat/


Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX. 

For more information about 2cureX:

Ole Thastrup, CEO;        

E-mail: ot@2cureX.com

Phone: +45 22 11 53 99;               

URL: www.2curex.com

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).